SCHEMBL2860292

SCHEMBL2860292

O=C(O)c1cnn(Cc2nc(-c3cc(OCc4ccccc4)cc(C(F)(F)F)c3)cs2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALKBH1 Q13686 7/20 0.42
PPARD Q03181 1/20 0.41
EGLN1 Q9GZT9 3/20 0.41
MRGPRX4 Q96LA9 2/20 0.41
NR4A2 P43354 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
KLKB1 P03952 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868652 0.94 ALKBH1 (0.45) ALDH1A1MEN1KMT2AKDM4EALKBH1
SCHEMBL1198589 0.93 MMP13 (0.40) ALDH1A1MEN1KMT2AKDM4EPPARD
SCHEMBL2859042 0.93 ALKBH1 (0.49) ALDH1A1MEN1KMT2AKDM4EALKBH1
SCHEMBL2861490 0.92 ALKBH1 (0.44) ALDH1A1MEN1KMT2AKDM4EALKBH1
SCHEMBL1198715 0.92 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AKDM4EALKBH1
Trifluoroacetic Acid SCHEMBL2863073 0.91 GPR132 (0.39) ALDH1A1MEN1KMT2AKDM4EPPARD
SCHEMBL12876610 0.90 PPARD (0.39) ALDH1A1MEN1KMT2AKDM4EPPARD
Trifluoroacetic Acid SCHEMBL2857015 0.88 PPARD (0.38) ALDH1A1MEN1KMT2AKDM4EPPARD
SCHEMBL2861391 0.88 KDM4E (0.40) ALDH1A1MEN1KMT2AKDM4EPPARD
SCHEMBL1197965 0.86 ALKBH1 (0.49) ALDH1A1MEN1KMT2AKDM4EALKBH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
WO-2009123316-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885MEN1 2661/4885KMT2A 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.